Natco Pharma received approval for Semaglutide from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March`26. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Powered by Capital Market - Live News

NATCO Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical Ingredient Division located in Manali, Chennai from 17 November - 21 November 2025. The Company received seven (7) observation in the Form-483. Further, the Company has received the EIR (Establishment Inspection Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI). Powered by Capital Market - Live News

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 February 2026, inter alia, have recommended the Third interim dividend of Rs 1.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Natco Pharma rose 13.91% to Rs 151.50 crore in the quarter ended December 2025 as against Rs 133.00 crore during the previous quarter ended December 2024. Sales rose 36.33% to Rs 647.30 crore in the quarter ended December 2025 as against Rs 474.80 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales647.30474.80 36 OPM %24.528.17 - PBDT207.30210.70 -2 PBT161.10163.70 -2 NP151.50133.00 14 Powered by Capital Market - Live News

NATCO Pharma received tentative approval from the USFDA for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa� by Janssen Biotech Inc. NATCO`s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy. Erdafitinib tablets had estimated sales of approximately USD 60 million in the U.S. for 12 months ending Sep`25 as per industry sales data.Powered by Capital Market - Live News